ascopubs.org

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684

A significant prolongation of relapse-free survival (P = .0023, one-sided) and prolongation of overall survival (P = .0237, one-sided) was observed with IFN alpha-2b therapy in this trial, which is ...
ascopubs.org

Interferon Alfa Therapy for Malignant Melanoma: A Systematic Review of Randomized Controlled Trials

PURPOSE: No standard systemic adjuvant therapy has been proven to increase overall survival in melanoma patients. The effect of interferon alfa (IFNα) as a single agent or in combination has been ...
Healio

Interferon-alpha may be used as biomarker for cutaneous lupus erythematosus, flares

Please provide your email address to receive an email when new articles are posted on . 38% of patients with cutaneous lupus erythematosus displayed evidence of positive interferon (IFN)-alpha ...
Targeted Oncology

ENDURE: No Added Benefit With Ropeginterferon Alfa-2b After TKI Stoppage in CML

Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...
Business Wire

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
Renal & Urology News

Pharmacodynamics and Viral Kinetics during Albinterferon Alfa-2b Therapy of Chronic Hepatitis C Genotype 1 Treatment-Naïve Patients

In this study, mathematical modeling of viral kinetics combined with pharmacokinetics was used to evaluate the pharmacodynamic properties of alb-IFN, a long-acting IFN being investigated for treatment ...